Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.48337
Caglar Unal
Objectives: This study aimed to evaluate the clinical outcomes, including progression-free survival (PFS), overall survival (OS), Objective Response Rate (ORR)
{"title":"Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye","authors":"Caglar Unal","doi":"10.14744/ejmo.2023.48337","DOIUrl":"https://doi.org/10.14744/ejmo.2023.48337","url":null,"abstract":"Objectives: This study aimed to evaluate the clinical outcomes, including progression-free survival (PFS), overall survival (OS), Objective Response Rate (ORR)","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135103376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.14744/ejmo.2023.43161
Liang Xiao
P enile cancer (PeCa) is a rare disease representing 0.4– 0.6% of all male malignant cancers, and more than 95% of patients were histologically classified as penile squamous cell carcinoma (pSCC). [1] PSCC primarily presents as a painless ulcer or lump on the glans penis, recognized by invasive growth and early lymphatic metastasis. [2,3] As for Penile squamous cell carcinoma (pSCC) is a rare malignancy of urinary system. Patients with advanced and metastasized pSCC are associated with poor prognosis due to the limited treatments options of pSCC. In our case report, we describe a patient diagnosed with early stage (stage IIA) and well differentiated pSCC. However, the well differentiated penile squamous cell carcinoma had showed an unexpected aggressiveness. The patient had two times rapid relapse with local advanced and metastasis after two radical operation. As received multimodal treatments including chemotherapy, immunotherapy and local ablation therapy and radiotherapy, the patient had got progression free survival (PFS) exceeding 26 months and overall survival (OS) exceeding 44 months. Immunotherapy combined with ablation therapy and radiotherapy may reverse the biological behavior of penile squamous cell carcinoma.
{"title":"Immunotherapy Combined with Microwave Ablation and Radiotherapy Reversed the Biological Behavior of Penile Squamous Cell Carcinoma: A Case Report and Literature Review","authors":"Liang Xiao","doi":"10.14744/ejmo.2023.43161","DOIUrl":"https://doi.org/10.14744/ejmo.2023.43161","url":null,"abstract":"P enile cancer (PeCa) is a rare disease representing 0.4– 0.6% of all male malignant cancers, and more than 95% of patients were histologically classified as penile squamous cell carcinoma (pSCC). [1] PSCC primarily presents as a painless ulcer or lump on the glans penis, recognized by invasive growth and early lymphatic metastasis. [2,3] As for Penile squamous cell carcinoma (pSCC) is a rare malignancy of urinary system. Patients with advanced and metastasized pSCC are associated with poor prognosis due to the limited treatments options of pSCC. In our case report, we describe a patient diagnosed with early stage (stage IIA) and well differentiated pSCC. However, the well differentiated penile squamous cell carcinoma had showed an unexpected aggressiveness. The patient had two times rapid relapse with local advanced and metastasis after two radical operation. As received multimodal treatments including chemotherapy, immunotherapy and local ablation therapy and radiotherapy, the patient had got progression free survival (PFS) exceeding 26 months and overall survival (OS) exceeding 44 months. Immunotherapy combined with ablation therapy and radiotherapy may reverse the biological behavior of penile squamous cell carcinoma.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86669576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy","authors":"H. Yıldırım","doi":"10.14744/ejmo.2022.78280","DOIUrl":"https://doi.org/10.14744/ejmo.2022.78280","url":null,"abstract":"DOI: 10.14744/ejmo.2022.78280 EJMO 2022;6(1):59–63 Eurasian Journal of Medicine and Oncology","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"40 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91347981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.14744/ejmo.2021.65852
S. Mahalakshmi
{"title":"Patient on Antithrombotics Drugs: Communication Between the Dentist and the Physician","authors":"S. Mahalakshmi","doi":"10.14744/ejmo.2021.65852","DOIUrl":"https://doi.org/10.14744/ejmo.2021.65852","url":null,"abstract":"","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"171 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74869309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.14744/ejmo.2022.77974
yi hau lu
We read with great interest the article by Vitale et al.,[1] who examined 6882 patients with hepatocellular carcinoma (HCC) in Italy to estimate the prevalence of metabolic-associated fatty liver disease (MAFLD).[1] They found the prevalence of MAFLD to be increasing rapidly among such patients in Italy. They also found that patients with MAFLD-related HCC were at a lower risk of HCC-related death than patients with other HCC subtypes. We applaud the investigators for providing important insights into the prevalence of MAFLD-related HCC. However, we wish to draw attention to some points to place their findings in perspective. Vitale et al. reported that they diagnosed patients with MAFLD if they were overweight or obese, defined as a body mass index > 25 kg/m2, or had type 2 diabetes mellitus, or showed evidence of metabolic disorders.[1] This is not entirely consistent with international consensus guidelines, according to which MAFLD should be diagnosed based on the presence of fatty liver as well as one of the following: overweight/obesity, type 2 diabetes mellitus, or lean/normal weight with evidence of metabolic disorders.[2] In addition, Vitale et al. apparently did not assess waist circumference, insulin resistance, or levels of C-reactive protein, which should also be taken into account when diagnosing MAFLD. Even if the prevalence reported by Vitale et al. can be taken to reflect bona fide MAFLD, we are concerned about whether it can be extrapolated to the larger population of HCC patients in Italy or elsewhere. Among the 6882 patients whom Vitale et al. enrolled consecutively from January 2002 to December 2019, 17.1% had single-etiology MAFLD and 51.2% had mixed-etiology MAFLD, while 31.6% did not have MAFLD. These proportions differed significantly from the corresponding proportions of 10.9%, 30.1%, and 59.0% from another sample of Italian HCC patients[3] (p<0.001, Fig. 1a) despite the fact that the enrollment window of the second sample lay within that of the sample of Vitale et al., and some patients in both samples came from the same medical center. Vitale et al. combined the prevalences of singleand mixed-etiology MAFLD to give an overall prevalence of MAFLD-related HCC of 68.3%,[1] which is significantly higher than the 12.8%[4] or 19.8%[5] in Mainland China or 38.8% in Taiwan[6] (both p<0.001, Fig. 1a). The latter two prevalences seem more reasonable to us given recent estimates of the global prevalence of MAFLD as 39.2% in the general Yu-Xian Teng,1 Hao-Tian Liu,1 Zhu-Jian Deng,1 Jia-Yong Su,1 Yi-Hua Lu,1 Jian-Hong Zhong1,2
{"title":"Prevalence of MAFLD-Related Hepatocellular Carcinoma","authors":"yi hau lu","doi":"10.14744/ejmo.2022.77974","DOIUrl":"https://doi.org/10.14744/ejmo.2022.77974","url":null,"abstract":"We read with great interest the article by Vitale et al.,[1] who examined 6882 patients with hepatocellular carcinoma (HCC) in Italy to estimate the prevalence of metabolic-associated fatty liver disease (MAFLD).[1] They found the prevalence of MAFLD to be increasing rapidly among such patients in Italy. They also found that patients with MAFLD-related HCC were at a lower risk of HCC-related death than patients with other HCC subtypes. We applaud the investigators for providing important insights into the prevalence of MAFLD-related HCC. However, we wish to draw attention to some points to place their findings in perspective. Vitale et al. reported that they diagnosed patients with MAFLD if they were overweight or obese, defined as a body mass index > 25 kg/m2, or had type 2 diabetes mellitus, or showed evidence of metabolic disorders.[1] This is not entirely consistent with international consensus guidelines, according to which MAFLD should be diagnosed based on the presence of fatty liver as well as one of the following: overweight/obesity, type 2 diabetes mellitus, or lean/normal weight with evidence of metabolic disorders.[2] In addition, Vitale et al. apparently did not assess waist circumference, insulin resistance, or levels of C-reactive protein, which should also be taken into account when diagnosing MAFLD. Even if the prevalence reported by Vitale et al. can be taken to reflect bona fide MAFLD, we are concerned about whether it can be extrapolated to the larger population of HCC patients in Italy or elsewhere. Among the 6882 patients whom Vitale et al. enrolled consecutively from January 2002 to December 2019, 17.1% had single-etiology MAFLD and 51.2% had mixed-etiology MAFLD, while 31.6% did not have MAFLD. These proportions differed significantly from the corresponding proportions of 10.9%, 30.1%, and 59.0% from another sample of Italian HCC patients[3] (p<0.001, Fig. 1a) despite the fact that the enrollment window of the second sample lay within that of the sample of Vitale et al., and some patients in both samples came from the same medical center. Vitale et al. combined the prevalences of singleand mixed-etiology MAFLD to give an overall prevalence of MAFLD-related HCC of 68.3%,[1] which is significantly higher than the 12.8%[4] or 19.8%[5] in Mainland China or 38.8% in Taiwan[6] (both p<0.001, Fig. 1a). The latter two prevalences seem more reasonable to us given recent estimates of the global prevalence of MAFLD as 39.2% in the general Yu-Xian Teng,1 Hao-Tian Liu,1 Zhu-Jian Deng,1 Jia-Yong Su,1 Yi-Hua Lu,1 Jian-Hong Zhong1,2","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73683145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.14744/ejmo.2023.79236
husnu tore yavuzsen
com-Objectives: The present study aims to evaluate the relationship between microribonucleic acid (miRNA) and target gene expressions with clinical and histopathological data in ovarian cancer. Methods: We evaluated 96 archival samples of paraffin-embedded tissue. Some potentially significant miRNA and target gene expressions were evaluated in different histopathological characteristics. These were quantified using real-time–polymerase chain reaction (RT–PCR) in tumor and normal tissue. In miRNA expressions, twofold changes are accepted as significant. Results: According to histopathological groups, 38 (39.6%) were endometroid adenocarcinoma, 11 (11.5%) were borderline serous, 29 (30.2%) were serous, and 18 (18.8%) were mucinous carcinoma. When evaluated according to their stages, 26 (27.1%) patients were stage 1A/1B. A relationship was found between miR200a and miR200c and histopathologic groups, between miR141 and estrogen receptors, between CXCL1 and survival status, and between KEAP1 and ki67. Additionally, miR200a in endometrial and miR200c in mucinous adenocarcinoma were overexpressed. When the relationship between all miRNAs and histopathological groups was evaluated, a significant change was found only in miR200c expression. It was significantly higher in serous than endometrial tumors and significantly higher in mucinous than endometroid tumors. Conclusion: These suggested that miR200a and 200c expressions might be useful for the evaluation of histopathological subgroups of ovarian cancer.
{"title":"Evaluation of MicroRNA Expressions in Ovarian Cancer","authors":"husnu tore yavuzsen","doi":"10.14744/ejmo.2023.79236","DOIUrl":"https://doi.org/10.14744/ejmo.2023.79236","url":null,"abstract":"com-Objectives: The present study aims to evaluate the relationship between microribonucleic acid (miRNA) and target gene expressions with clinical and histopathological data in ovarian cancer. Methods: We evaluated 96 archival samples of paraffin-embedded tissue. Some potentially significant miRNA and target gene expressions were evaluated in different histopathological characteristics. These were quantified using real-time–polymerase chain reaction (RT–PCR) in tumor and normal tissue. In miRNA expressions, twofold changes are accepted as significant. Results: According to histopathological groups, 38 (39.6%) were endometroid adenocarcinoma, 11 (11.5%) were borderline serous, 29 (30.2%) were serous, and 18 (18.8%) were mucinous carcinoma. When evaluated according to their stages, 26 (27.1%) patients were stage 1A/1B. A relationship was found between miR200a and miR200c and histopathologic groups, between miR141 and estrogen receptors, between CXCL1 and survival status, and between KEAP1 and ki67. Additionally, miR200a in endometrial and miR200c in mucinous adenocarcinoma were overexpressed. When the relationship between all miRNAs and histopathological groups was evaluated, a significant change was found only in miR200c expression. It was significantly higher in serous than endometrial tumors and significantly higher in mucinous than endometroid tumors. Conclusion: These suggested that miR200a and 200c expressions might be useful for the evaluation of histopathological subgroups of ovarian cancer.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87916186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Varicella-Zoster Virus Infection and Brivudine Therapy: Unexpected Response in Sarcoma Patient","authors":"O. Kostek","doi":"10.14744/ejmo.2022.26330","DOIUrl":"https://doi.org/10.14744/ejmo.2022.26330","url":null,"abstract":"DOI: 10.14744/ejmo.2022.26330 EJMO 2022;6(2):182–185","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91469302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.14744/ejmo.2021.21883
Hao Liu
For more than a decade, the targeted drug sorafenib[1, 2] has been the dominant first-line treatment for patients with advanced hepatocellular carcinoma (HCC). However, due to the low overall response rate and high drug resistance rate, many new targeted drugs have been developed, including sunitinib, brivanib, linifanib, nintedanib, dovitinib, sorafenib plus erlotinib, lenvatinib, and donafenib. On the other hand, with the increasing use of immune checkpoint inhibitors in solid tumors, several trials investigated the efficacy and safety of immune checkpoint inhibitors in advanced HCC. Among these trials, only lenvatinib and donafenib as monotherapy were non-inferior to sorafenib in overall survival in untreated advanced HCC. Most of other trials did not meet their primary end point of overall survival. However, the efficacy of the combination therapy with PD-1 or PD-L1 inhibitor plus bevacizumab (VEGF inhibitor) is amazing.[3, 4] An expert panel convened by the American Association for the Study of Liver Diseases recommended time to progression as the primary endpoint in randomized phase 2 trials and overall survival as the main endpoint to measure effectiveness in phase 3 trials.[5, 6] In real world clinical practice, subsequent antitumor therapies after tumor progression and/or therapies for concurrent liver disease can confound the assessment of clinical benefit. In the recent issue of Journal of Hepatology, on behalf of EASL, Bruix and coworkers updated the recommendations of systemic treatment of HCC.7 This review proposed that “overall survival is the sole robust endpoint to assess the benefit from any intervention in advanced HCC” and “all proposed surrogates lack adequate validation”. Here, we tried to reveal the relationship among objective response rate (ORR), median overall survival (OS) time and median progression-free survival (PFS) time by presenting them in a same curve graph. The potential relationship between PFS and OS is revealed by representing the hazard ratio (with 95% confidence interval) of PFS and OS with a forest plot. We systematically searched PubMed and EMBASE databases and analyzed phase 3 clinical trials with large sample size. A total of 11 trials about first-line systemic therapies for advanced HCC published from 2008 to 2021 were included into analysis. All these 11 trials included a group of patients treated with sorafenib. In addition, 7 trials about second-line systemic therapies published from 2015 to 2021 were also included into analysis. The control group received placebo treatment in all these 7 trials. All these 18 trials reported ORR, median PFS and OS time. The ORR according to RECIST 1.1 in the sorafenib group ranged from 0.7% to 11.9% (median 6.1%). Among patients with sorafenib therapy, the median PFS and OS time was 3.75 (range 2.8 to 5.5) and 10.4 (range 6.5 to 14.7) months, reHao-Tian Liu,2 Yu-Hong Sun,1 Zhu-Jian Deng,2 Zi-Yi Zhang,2 Da-Long Yang,2 Kun-Jun Wu2 Xiao-Bu Lan,1
{"title":"Surrogate Indicators of Overall Survival in Advanced Hepatocellular Carcinoma","authors":"Hao Liu","doi":"10.14744/ejmo.2021.21883","DOIUrl":"https://doi.org/10.14744/ejmo.2021.21883","url":null,"abstract":"For more than a decade, the targeted drug sorafenib[1, 2] has been the dominant first-line treatment for patients with advanced hepatocellular carcinoma (HCC). However, due to the low overall response rate and high drug resistance rate, many new targeted drugs have been developed, including sunitinib, brivanib, linifanib, nintedanib, dovitinib, sorafenib plus erlotinib, lenvatinib, and donafenib. On the other hand, with the increasing use of immune checkpoint inhibitors in solid tumors, several trials investigated the efficacy and safety of immune checkpoint inhibitors in advanced HCC. Among these trials, only lenvatinib and donafenib as monotherapy were non-inferior to sorafenib in overall survival in untreated advanced HCC. Most of other trials did not meet their primary end point of overall survival. However, the efficacy of the combination therapy with PD-1 or PD-L1 inhibitor plus bevacizumab (VEGF inhibitor) is amazing.[3, 4] An expert panel convened by the American Association for the Study of Liver Diseases recommended time to progression as the primary endpoint in randomized phase 2 trials and overall survival as the main endpoint to measure effectiveness in phase 3 trials.[5, 6] In real world clinical practice, subsequent antitumor therapies after tumor progression and/or therapies for concurrent liver disease can confound the assessment of clinical benefit. In the recent issue of Journal of Hepatology, on behalf of EASL, Bruix and coworkers updated the recommendations of systemic treatment of HCC.7 This review proposed that “overall survival is the sole robust endpoint to assess the benefit from any intervention in advanced HCC” and “all proposed surrogates lack adequate validation”. Here, we tried to reveal the relationship among objective response rate (ORR), median overall survival (OS) time and median progression-free survival (PFS) time by presenting them in a same curve graph. The potential relationship between PFS and OS is revealed by representing the hazard ratio (with 95% confidence interval) of PFS and OS with a forest plot. We systematically searched PubMed and EMBASE databases and analyzed phase 3 clinical trials with large sample size. A total of 11 trials about first-line systemic therapies for advanced HCC published from 2008 to 2021 were included into analysis. All these 11 trials included a group of patients treated with sorafenib. In addition, 7 trials about second-line systemic therapies published from 2015 to 2021 were also included into analysis. The control group received placebo treatment in all these 7 trials. All these 18 trials reported ORR, median PFS and OS time. The ORR according to RECIST 1.1 in the sorafenib group ranged from 0.7% to 11.9% (median 6.1%). Among patients with sorafenib therapy, the median PFS and OS time was 3.75 (range 2.8 to 5.5) and 10.4 (range 6.5 to 14.7) months, reHao-Tian Liu,2 Yu-Hong Sun,1 Zhu-Jian Deng,2 Zi-Yi Zhang,2 Da-Long Yang,2 Kun-Jun Wu2 Xiao-Bu Lan,1","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"30 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91521646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.14744/ejmo.2022.78475
M. Khyatti
In-Objectives: Interleukin-10 (IL10) is a pro-inflammatory cytokine that plays a pivotal role in inflammatory diseases as well as in the pathogenesis of diverse tumors, including nasopharyngeal carcinoma (NPC). The present study was designed to evaluate the importance of the functional promoter polymorphisms of IL10 (-1082 A>G and -592 A>C) in the development of NPC. Methods: A total of 384 patients with NPC were recruited into this study, together with 375 matched control subjects. Polymorphisms within the promoter region of IL10 gene were analysed using PCR-RFLP method. Results: We report a lack of association between IL10 polymorphisms and NPC in the overall population (P>0.05). How-ever, the 1082 A>G polymorphism was significantly associated with the susceptibility to NPC among young patients (age ≤30 years). The GG genotype was found to be associated with a significantly higher risk of NPC as compared with the AA genotype among young patients (OR=2.534; 95% CI, 1.189–5.398, P=0.016). Conclusion: The results of the present study indicate an association between IL10 -1082 GG genotype and NPC among young North African subjects. This difference in IL10 polymorphism association with different ages at the onset of NPC suggests that the younger and older onset patients are genetically different and may involve different mechanisms. Abstract Article: Moumad K, Khaali W, Benider A, Ayoub WB, Cherif MH, Boualga K, et al. The Involvement of Interleukin-10 Promoter Genetic Polymorphism in Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma from North Africa.
{"title":"The Involvement of Interleukin-10 Promoter Genetic Polymorphism in Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma from North Africa","authors":"M. Khyatti","doi":"10.14744/ejmo.2022.78475","DOIUrl":"https://doi.org/10.14744/ejmo.2022.78475","url":null,"abstract":"In-Objectives: Interleukin-10 (IL10) is a pro-inflammatory cytokine that plays a pivotal role in inflammatory diseases as well as in the pathogenesis of diverse tumors, including nasopharyngeal carcinoma (NPC). The present study was designed to evaluate the importance of the functional promoter polymorphisms of IL10 (-1082 A>G and -592 A>C) in the development of NPC. Methods: A total of 384 patients with NPC were recruited into this study, together with 375 matched control subjects. Polymorphisms within the promoter region of IL10 gene were analysed using PCR-RFLP method. Results: We report a lack of association between IL10 polymorphisms and NPC in the overall population (P>0.05). How-ever, the 1082 A>G polymorphism was significantly associated with the susceptibility to NPC among young patients (age ≤30 years). The GG genotype was found to be associated with a significantly higher risk of NPC as compared with the AA genotype among young patients (OR=2.534; 95% CI, 1.189–5.398, P=0.016). Conclusion: The results of the present study indicate an association between IL10 -1082 GG genotype and NPC among young North African subjects. This difference in IL10 polymorphism association with different ages at the onset of NPC suggests that the younger and older onset patients are genetically different and may involve different mechanisms. Abstract Article: Moumad K, Khaali W, Benider A, Ayoub WB, Cherif MH, Boualga K, et al. The Involvement of Interleukin-10 Promoter Genetic Polymorphism in Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma from North Africa.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"30 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83099712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：